$BCYC

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results Nuzefatide pevedotin granted FDA Orphan Drug Designation for the treatment of pancreatic cancer; further updates expected in 2027 Initiation of the first company-sponsored

Bicycle Therapeutics (BCYC) reported Q3 2026 results, with cash of $469.9M and collaboration revenue of $34.1M. The FDA granted Orphan Drug Designation to nuzefatide pevedotin for pancreatic cancer. The company expects its cash runway to extend into 2030 and plans to initiate a radioligand clinical trial for BT1702 in 2H 2027. Net loss was $10.5M, or $0.15 per share, compared to $59.1M, or $0.85 per share, in Q3 2025.

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the “Board”) of Bicycle The

Bicycle Therapeutics (NASDAQ: BCYC) reported Q2 2026 results and business updates. It cited AACR/ASCO data for nuzefatide in EphA2-expressing cancers, including Phase 2 recurrent pancreatic cancer with first patient dosed in April 2026. Cash was $510.1M at June 30, 2026, funding into 2030. Duravelo-2 interim Week 27 ORR was 65% (17/26).

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology therapeutics with improved benefit/risk profiles co

BICYCLE THERAPEUTICS PLC (BCYC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001761612 X0 00-0000000 true 0001761612 2026-06-17 2026-06-17 0001761612 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001761612 bcyc:AmericanDepositarySharesMember 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCH

Bicycle Therapeutics reported its Q4 and full-year 2025 financial results, alongside a strategic reprioritization. The company will focus on next-generation therapeutics like BT5528 and Bicycle Radioconjugates, while deprioritizing zelenectide's internal development and converting its trial to a randomized Phase 2 study. This strategic shift includes a 30% workforce reduction to extend its cash runway into 2030, and the company has established partnerships to secure an end-to-end supply chain for its radiopharmaceutical pipeline.

Westfield Capital Management Company, L.P. filed an Amendment No. 2 to a Schedule 13G, reporting that it beneficially owned 0 shares of Bicycle Therapeutics plc (NASDAQ: BCYC) common stock as of December 31, 2025. The filing indicates no voting or dispositive power held by Westfield for BCYC shares. The amendment was signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, and dated March 3, 2026.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Delhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms & Market Opportunity Insight 2025 Report Highlights: